NASDAQ:SGTX

Sigilon Therapeutics Competitors

$17.43
-0.33 (-1.86 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.55
Now: $17.43
$17.97
50-Day Range
$17.76
MA: $23.86
$35.88
52-Week Range
$16.55
Now: $17.43
$54.32
Volume46,188 shs
Average Volume130,559 shs
Market Capitalization$548.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Sigilon Therapeutics (NASDAQ:SGTX) Vs. NUVB, IBRX, BCAB, IMCR, EWTX, and KNTE

Should you be buying SGTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Sigilon Therapeutics, including Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cricut (EWTX), and Kinnate Biopharma (KNTE).

Nuvation Bio (NYSE:NUVB) and Sigilon Therapeutics (NASDAQ:SGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Nuvation Bio and Sigilon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Sigilon Therapeutics01302.75

Nuvation Bio currently has a consensus target price of $17.40, suggesting a potential upside of 74.00%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Nuvation Bio.

Valuation and Earnings

This table compares Nuvation Bio and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Nuvation Bio and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

Nuvation Bio beats Sigilon Therapeutics on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for ImmunityBio and Sigilon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Sigilon Therapeutics01302.75

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 55.38%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than ImmunityBio.

Valuation and Earnings

This table compares ImmunityBio and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares ImmunityBio and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

Sigilon Therapeutics beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for BioAtla and Sigilon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Sigilon Therapeutics01302.75

BioAtla currently has a consensus target price of $58.00, suggesting a potential upside of 20.26%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than BioAtla.

Valuation and Earnings

This table compares BioAtla and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares BioAtla and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

BioAtla beats Sigilon Therapeutics on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Immunocore and Sigilon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Sigilon Therapeutics01302.75

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 68.63%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Immunocore and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

Sigilon Therapeutics beats Immunocore on 3 of the 3 factors compared between the two stocks.

Cricut (NASDAQ:EWTX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Cricut and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CricutN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cricut and Sigilon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cricut0000N/A
Sigilon Therapeutics01302.75

Sigilon Therapeutics has a consensus price target of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Cricut.

Valuation & Earnings

This table compares Cricut and Sigilon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CricutN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Summary

Sigilon Therapeutics beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Kinnate Biopharma and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kinnate BiopharmaN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Kinnate Biopharma and Sigilon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kinnate Biopharma00403.00
Sigilon Therapeutics01302.75

Kinnate Biopharma currently has a consensus price target of $52.00, suggesting a potential upside of 73.39%. Sigilon Therapeutics has a consensus price target of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Kinnate Biopharma.

Valuation & Earnings

This table compares Kinnate Biopharma and Sigilon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kinnate BiopharmaN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Summary

Kinnate Biopharma beats Sigilon Therapeutics on 2 of the 3 factors compared between the two stocks.


Sigilon Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00-0.0%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.09-4.8%$1.76 billionN/A0.00Analyst Revision
BioAtla logo
BCAB
BioAtla
1.5$48.23-1.8%$1.62 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$32.22-10.1%$1.39 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$28.61-3.3%$1.36 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$29.99-5.2%$1.30 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$29.87-8.1%$1.30 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$35.15-8.3%$1.23 billionN/A0.00Analyst Revision
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.13-0.3%$1.19 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.63-9.4%$1.18 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.05-0.3%$951.68 millionN/A0.00Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.01-2.3%$923.52 millionN/A0.00News Coverage
FDMT
4D Molecular Therapeutics
1.3$34.42-9.5%$918.81 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.89-2.8%$910.67 millionN/A0.00Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.27-11.3%$851.85 millionN/A0.00Insider Selling
Analyst Revision
PHAR
Pharming Group
0.0$12.80-3.6%$816.72 millionN/A0.00Gap Up
FNCH
Finch Therapeutics Group
0.3$17.10-0.5%$806.18 millionN/A0.00News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$21.84-6.2%$793.40 millionN/A0.00Analyst Revision
Inventiva logo
IVA
Inventiva
1.4$14.35-0.6%$554.34 millionN/A0.00News Coverage
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$12.59-5.0%$541.36 millionN/A0.00Analyst Revision
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.74-6.7%$445.72 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.50-2.6%$443.53 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.81-4.5%$436.66 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.74-4.7%$426.49 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.15-2.2%$407.20 millionN/A0.00
PRTG
Portage Biotech
0.0$28.97-0.9%$350.05 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.60-4.1%$306.31 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.99-1.1%$296.84 millionN/A-2.76
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.53-0.1%$262.22 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$12.31-0.2%$235.36 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$12.99-23.2%$219.75 millionN/A0.00Analyst Revision
Annovis Bio logo
ANVS
Annovis Bio
0.0$25.07-5.9%$174.16 millionN/A0.00
GANX
Gain Therapeutics
1.0$14.00-0.1%$158.63 millionN/A0.00Analyst Report
News Coverage
Gap Down
Trading Halted
VINC
Vincerx Pharma
1.0$18.62-2.4%$152.78 millionN/A0.00
LGVN
Longeveron
0.3$6.92-1.6%$129.45 millionN/A0.00News Coverage
EVAX
Evaxion Biotech A/S
1.7$6.40-4.8%$122.87 millionN/A0.00Analyst Revision
Gap Down
UPC
Universe Pharmaceuticals
0.0$4.22-10.0%$91.79 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.73-0.4%$61.47 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.56-1.1%$55.88 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.99-3.0%$49.90 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.72-4.0%$43.82 millionN/A0.00News Coverage
VLON
Vallon Pharmaceuticals
0.3$4.44-5.0%$30.24 millionN/A0.00High Trading Volume
VRPX
Virpax Pharmaceuticals
0.3$4.78-1.7%$23.64 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$39.73-15.5%$18.44 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.71-8.4%$15.16 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.92-32.9%$3.03 millionN/A0.00High Trading Volume
News Coverage
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.05-5.6%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.72-8.1%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.